Netherton Syndrome Treatment Market Size in the 7MM was valued at ~USD 25 million in 2024 and it is expected to grow by 2034, estimates DelveInsight

DelveInsight's "Netherton Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Netherton Syndrome, historical and forecasted epidemiology as well as the Netherton Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Unlock key insights into the Netherton Syndrome Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Netherton Syndrome Market Size- https://www.delveinsight.com/sample-request/netherton-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the key facts of the Netherton Syndrome Market Report
• On 28 October 2025, Quoin Pharmaceuticals conducted a study has been designed to determine the safety, tolerability and efficacy of QRX003 lotion 2%, 4% QAM or 4% BID in subjects with Netherton Syndrome (NS) in comparison to vehicle.
• On 10 October 2025, Boehringer Ingelheim announced a study is open to people with a skin disease called Netherton syndrome (NS). People can join the study if they are 12 years or older. The purpose of this study is to find out whether a medicine called spesolimab helps people with NS.
• In EU4 and the UK, females constituted a higher proportion of affected individuals, accounting for approximately 58% of cases, compared to 42% in males, highlighting a notable gender disparity in disease burden.
• In 2024, Germany recorded the highest number of gender-specific diagnosed prevalent cases among EU4 and the UK, with approximately 245 cases in females and 175 cases in males.
• According to DelveInsight analysis, in 2024, there were nearly 300 diagnosed prevalent cases of Netherton syndrome reported in Italy.
• In 2024, Japan reported approximately 123 identified cases of Netherton syndrome, highlighting the condition's rarity and limited patient population.
• The leading Netherton Syndrome Companies such as Lifemax Laboratories, AnaptysBio, Janssen Biotech, Northwestern University, University Hospital, and others
• Promising Netherton Syndrome Therapies such as QRX003, SPEVIGO (spesolimab/BI 655130), LM-030 (BPR277), DS-2325a, Pimecrolimus, and others

Stay ahead in the competitive landscape of the Netherton Syndrome Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Netherton Syndrome Treatment Market Size- https://www.delveinsight.com/sample-request/netherton-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Netherton Syndrome Epidemiology Segmentation in the 7MM
• Total Prevalence of Netherton Syndrome
• Prevalent Cases of Netherton Syndrome by severity
• Gender-specific Prevalence of Netherton Syndrome
• Diagnosed Cases of Episodic and Chronic Netherton Syndrome

Download the report to understand which factors are driving Netherton Syndrome epidemiology trends @ Netherton Syndrome Prevalence- https://www.delveinsight.com/sample-request/netherton-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Netherton Syndrome Emerging Drugs
• ATR-12: Azitra
ATR-12, currently in Phase I development by Azitra for Netherton Syndrome, utilizes a bioengineered strain of Staphylococcus epidermidis (SE351) to topically deliver therapeutic levels of the lymphoepithelial Kazal-type-related inhibitor (LEKTI) protein-an essential serine protease inhibitor lacking in affected patients. By restoring LEKTI directly at the skin barrier, ATR-12 aims to address the underlying protein deficiency driving the disease. Notably, ATR-12 has also received RPDD from the US FDA, underscoring its potential as a promising therapeutic approach for this underserved pediatric population

• DS-2325: Daiichi Sankyo
DS-2325 is an investigational drug developed by Daiichi Sankyo for Netherton syndrome, a severe genetic skin disorder characterized by widespread scaling. DS-2325 works by selectively inhibiting KLK5, a serine protease that becomes hyperactive in Netherton syndrome due to deficient LEKTI protein levels. This hyperactivity leads to uncontrolled skin shedding and inflammation. By blocking KLK5, DS-2325 aims to restore protease balance, improve epidermal barrier function, and reduce symptoms like scaling and redness. DS-2325 has received multiple regulatory designations from the US FDA, including Orphan Drug Designation (ODD), Fast Track Designation (FTD), and RPDD. These designations are expected to facilitate a smoother and potentially accelerated approval process, ultimately helping to make the therapy more accessible to patients in need. The current trial has been terminated, though the company has not formally withdrawn the program at this stage.

• SPEVIGO: Boehringer Ingelheim
SPEVIGO (spesolimab) is a humanized monoclonal antibody (mAb) that targets the interleukin-36 receptor (IL-36R). It is currently under clinical development for Netherton syndrome-a rare, inherited skin disorder characterized by chronic inflammation, scaling, and hair abnormalities. SPEVIGO is currently in Phase II/III clinical trials as a potential treatment for Netherton syndrome and has also received ODD from the US FDA for this indication.

Netherton Syndrome Therapies and Companies
• QRX003: Quoin Pharmaceutical
• SPEVIGO (spesolimab/BI 655130): Boehringer Ingelheim
• LM-030 (BPR277): LifeMax Laboratories/Novartis
• DS-2325a: Daiichi Sankyo
• Pimecrolimus: Children's Hospital of Philadelphia

Discover the future of Netherton Syndrome treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Netherton Syndrome Market Drivers and Barriers- https://www.delveinsight.com/sample-request/netherton-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Netherton Syndrome Drugs Market Insights
Current Netherton Syndrome Treatment approaches are limited to symptom relief or supportive care with marginal efficacy and undesirable side effects. A gentle/soft non-detergent liquid cleansing oil, preferably with an acidic pH to counteract overactive serine proteases, is recommended for daily baths and/or showers. Several classes of drugs are being used to manage Netherton syndrome, including emollients, antihistamines, topical corticosteroids, calcineurin inhibitors, calcipotriol, retinoids, immunoglobulins, antibiotics, and others. The pathogenesis basis of Netherton syndrome is well understood,with a definite link to mutations in the SPINK5 gene that have led tothe discovery of potential pathways like IL-7 and KLK inhibition. Advocacy and support groups for Netherton syndrome are spreadingawareness and providing a platform for medical experts,researchers, and patients to collaborate. IV immunoglobulin therapy in pediatrics has presented effectiveresults, and continuous research in this area can lead to thedevelopment of disease-modifying therapies. Studies have demonstrated the potential of gene therapy ingenodermatosis. Thus, developing therapies like replacementtherapy and gene therapy can cure Netherton Syndrome.

Netherton Syndrome Market Outlook
There are currently no approved therapies specifically indicated for Netherton syndrome, and management largely relies on off-label and symptomatic treatments. Agents such as retinoids, immunosuppressants (topical and systemic), and anti-inflammatory medications are commonly employed, though their effectiveness in this rare condition remains incompletely validated. Biologics are also occasionally prescribed off-label, but conclusive evidence supporting their benefit is still limited. Symptomatic care typically includes emollients, keratolytics, and moisturizers to support skin barrier function and hydration.

Explore the dynamics of the Netherton Syndrome Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Netherton Syndrome Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/netherton-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Netherton Syndrome Market Report
• Coverage: 7MM
• Study Period: 2025-2034
• Netherton Syndrome Companies: Quoin Pharmaceutical, Boehringer Ingelheim, LifeMax Laboratories, Novartis, Daiichi Sankyo, Quoin Pharmaceuticals, Children's Hospital of Philadelphia, and others
• Netherton Syndrome Therapies: QRX003, SPEVIGO (spesolimab/BI 655130), LM-030 (BPR277), DS-2325a, Pimecrolimus, and others
• Netherton Syndrome Therapeutic Assessment: Netherton Syndrome current marketed and Netherton Syndrome emerging therapies
• Netherton Syndrome Market Dynamics: Netherton Syndrome market drivers and Netherton Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Netherton Syndrome Unmet Needs, KOL's views, Analyst's views, Netherton Syndrome Market Access and Reimbursement

Table of Contents
1. Netherton Syndrome Market Report Introduction
2. Executive Summary for Netherton Syndrome
3. SWOT analysis of Netherton Syndrome
4. Netherton Syndrome Patient Share (%) Overview at a Glance
5. Netherton Syndrome Market Overview at a Glance
6. Netherton Syndrome Disease Background and Overview
7. Netherton Syndrome Epidemiology and Patient Population
8. Country-Specific Patient Population of Netherton Syndrome
9. Netherton Syndrome Current Treatment and Medical Practices
10. Netherton Syndrome Unmet Needs
11. Netherton Syndrome Emerging Therapies
12. Netherton Syndrome Market Outlook
13. Country-Wise Netherton Syndrome Market Analysis (2020-2034)
14. Netherton Syndrome Market Access and Reimbursement of Therapies
15. Netherton Syndrome Market Drivers
16. Netherton Syndrome Market Barriers
17. Netherton Syndrome Appendix
18. Netherton Syndrome Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.